Panelists discuss emerging data comparing bladder-sparing therapies to radical cystectomy in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting the nuanced trade-offs in oncologic outcomes and quality of life, and emphasizing the need for shared decision-making as prospective studies like CISTO refine patient selection for personalized treatment strategies.
One key approach is to increase the representation of women on editorial boards of journals and as reviewers.
Karyn S. Eilber, MD,'s follow-up protocol involves a 2-week post-injection check-up to assess residual urine and the efficacy of the onabotA
The combination of zanzalintinib plus nivolumab demonstrated encouraging preliminary activity with manageable safety.
Panelists discuss how recent advancements in NMIBC treatment, including the approval of nadofaragene firadenovec, pembrolizumab, and intravesical therapies like TAR-200, have reshaped care for BCG-unresponsive patients, with promising developments and ongoing trials at AUA 2025 paving the way for more personalized and effective treatment strategies in the future.
Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access barriers, ensuring that NMIBC patients receive timely access to novel treatments like nadofaragene firadenovec and pembrolizumab.
Panelists discuss how overcoming challenges such as cost, insurance coverage, regulatory hurdles, patient selection, and the need for education is crucial for improving access to novel therapies like nadofaragene firadenovec and pembrolizumab, ultimately enhancing outcomes for NMIBC patients.
Loeb stressed the importance of individualized decision-making based on life expectancy and overall health rather than age alone.
"My goal [for] a lot of the advocacy that I do is that one day [patients] don't have to do our jobs for us," says Maria Uloko, MD.
“We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of what is important to them with values and preferences, as well as their individual prostate,” says Dean Elterman, MD, MSc.
Jad Chahoud, MD, MPH, MHA, discusses the mechanism of action for zanzalintinib and walks through key design elements of the STELLAR-002 trial.
Explore the complexities of treatment options for metastatic hormone-sensitive prostate cancer, emphasizing shared decision-making and patient considerations.
Research explores the effectiveness of Aerote in treating metastatic hormone-sensitive prostate cancer, focusing on patient subgroups and genetic factors.
“I think the big take-home message is now we've got multiple, multiple drugs showing that we can do significantly better than ADT alone," says Fred Saad, MD, FRCS.
Panelists discuss how the new tracing agent (Zr-DFO-girentuximab or 2050) works by binding to carbonic anhydrase IX, an enzyme expressed on the surface of most clear cell renal cancers, coupled with zirconium for radiographic detection.
Research highlights the need for personalized treatment in mHSPC, addressing variations in drug efficacy across diverse populations for optimal patient care.
Panelists discuss how the ZIRCON trial demonstrated high positive predictive value (> 90%) for identifying clear cell renal cell carcinoma using a new molecular imaging agent, though negative predictive value was lower at approximately 70%.
Research highlights the effectiveness and safety of mHSPC treatments for black men, ensuring they receive appropriate care and reassurance.
Panelists discuss how to approach treatment for a younger (49-year-old) male veteran with bladder cancer, focusing on the rising rates among veterans, challenges with recurrent disease despite BCG therapy, various second- and third-line treatment options, including gemcitabine-docetaxel combination therapy and the importance of thorough monitoring for disease progression.
Data showed a link between counties with higher rectal spacer use and a lower prevalence of ED at 4 to 5 years.
Panelists discuss the expanding treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer, highlighting the benefits and limitations of FDA-approved therapies like pembrolizumab, nadofaragene, and nogapendekin, alongside off-label use of gemcitabine-docetaxel, as clinicians strive to balance efficacy, accessibility, and individualized care amid ongoing resource challenges.
Panelists discuss the evolving definition of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), emphasizing its critical role in identifying patients who fail adequate BCG therapy, guiding next-line treatment decisions, and determining eligibility for clinical trials exploring novel therapeutic options.
EV+P demonstrated superior efficacy to chemotherapy across all specified subgroups assessed.
“There are a lot of variables and factors in deciding what might be the entire first-line of therapy," says Adam B. Weiner, MD.
Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer shows darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
The approval of darolutamide in mCSPC was supported by data from the phase 3 ARANOTE trial.
Paul E. Dato, MD, discusses how bone-targeted therapies play an important supportive role in advanced prostate cancer, with recommendations for calcium and vitamin D supplementation, vitamin K2 consideration, resistance exercises, and regular monitoring for all patients on ADT.
Panelists discuss how recent trials, including KEYNOTE-057, QUILT-3.032, and CORE-001, highlight the promising efficacy, durability, and manageable safety profiles of novel treatments like pembrolizumab, nogapendekin alfa inbakicept, and nadofaragene firadenovec, while also exploring the potential of combination therapies and novel intravesical options like TAR-200 and UGN-102 for improving outcomes in non–muscle-invasive bladder cancer (NMIBC).
Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety.
Paul E. Dato, MD, discusses how treatment selection between triplet therapy, doublet therapy, or androgen deprivation monotherapy should be based on disease volume, risk factors, patient age, fitness for chemotherapy, and patient preferences through shared decision-making.
